Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Development of An Integrated Pipeline for Early PD Prediction and Disease Modifying Drug Repurposing

Award Number: R01NS148533
ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/01/2026
PERIOD OF PERFORMANCE END DATE: 04/30/2031

Group Awards By:

View Award Description

Development of An Integrated Pipeline for Early PD Prediction and Disease Modifying Drug Repurposing - ABSTRACT Parkinson's Disease (PD) is the second most prevalent neurodegenerative disorder all over the world. It is estimated that PD affects 2-3% of people older than 65 years. PD is associated with serious dysfunctions with movement, speech, swallowing, and balance, as well as non-motor symptoms like depression, anxiety, sleep, and cognitive problems, significantly impacting daily activities and ultimately affecting the ability to live independently and maintain a good quality of life. As of now, PD remains pathologically and biologically unclear; and no disease-modifying treatment (DMT) current exist that can slow, halt, or reverse PD disease course. Prior neuropathological evidence indicates that PD pathology may begin up to two decades prior to clinical presentation–40–60% of dopaminergic neurons in the substantia nigra have been lost at time of motor symptom manifesting. Therefore, by the time PD is clinically diagnosed, neurodegeneration may be too advanced to be modified by therapeutic intervention. This has been recognized as a potential reason for the failure of many DMT trials. The pre-diagnostic or prodromal phases of PD (pPD) might represent a critical therapeutic window, during which molecular pathology may still be reversible or more responsive to intervention. In this context, this project aims at targeting the pPD phase to advance development of DMTs for early PD prevention. To this end, Aim 1 will develop an advanced AI-driven framework for harmonizing multimodal health data across PD research datasets, general-purpose biomedical databases, and large-scale EHR, and for building multimodal AI model for early prediction of PD. Aim 2 will develop causal learning-based trial emulation framework to identify and evaluate DMT repurposing candidates in PD, targeting the population with pPD. Aim 3 will leverage PD-derived iPSCs (in vitro) and mouse models (in vivo) for screening and validating the drug repurposing candidates.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $671,445 )
2026	2026	WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY	575 LEXINGTON AVE FL 9	NEW YORK	NY	10022	NEW YORK	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	1	5/4/2026	NEW	$671,445
														Subtotal = $671,445

Grand Total All Awards = $671,445

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development of An Integrated Pipeline for Early PD Prediction and Disease Modifying Drug Repurposing

Award Number: R01NS148533

ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/01/2026

PERIOD OF PERFORMANCE END DATE: 04/30/2031

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer